INNM.F Stock Overview
A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Amplia Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.059 |
| 52 Week High | AU$0.15 |
| 52 Week Low | AU$0.025 |
| Beta | 0.78 |
| 11 Month Change | -29.64% |
| 3 Month Change | -39.63% |
| 1 Year Change | 23.13% |
| 33 Year Change | -53.56% |
| 5 Year Change | 7.55% |
| Change since IPO | -62.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| INNM.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.8% | 4.0% | 2.2% |
| 1Y | 23.1% | 18.3% | 32.6% |
Return vs Industry: INNM.F exceeded the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: INNM.F underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| INNM.F volatility | |
|---|---|
| INNM.F Average Weekly Movement | 52.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INNM.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine INNM.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Chris Burns | www.ampliatx.com |
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer, other solid tumors, other fibrotic disease, and scar reduction which is in clinical trial. It also develops AMP886, which is in preclinical trial for treating solid tumors.
Amplia Therapeutics Limited Fundamentals Summary
| INNM.F fundamental statistics | |
|---|---|
| Market cap | US$15.72m |
| Earnings (TTM) | -US$2.93m |
| Revenue (TTM) | US$2.89m |
5.4x
P/S Ratio-5.4x
P/E RatioIs INNM.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INNM.F income statement (TTM) | |
|---|---|
| Revenue | AU$4.45m |
| Cost of Revenue | AU$441.99k |
| Gross Profit | AU$4.01m |
| Other Expenses | AU$8.51m |
| Earnings | -AU$4.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.016 |
| Gross Margin | 90.07% |
| Net Profit Margin | -101.14% |
| Debt/Equity Ratio | 13.1% |
How did INNM.F perform over the long term?
See historical performance and comparison